Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC36_35 FDC
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
**ASC36_35 FDC** is an investigational once-monthly subcutaneous fixed-dose combination for obesity developed by Ascletis. It co-formulates ASC36, a peptide amylin receptor agonist, with ASC35, a peptide dual glucagon-like peptide 1 receptor and glucose-dependent insulinotropic polypeptide receptor agonist. The combination is formulated as a self-assembling lipid depot long-acting injection intended to provide simultaneous amylin receptor, GLP-1 receptor, and GIP receptor agonism for body-weight reduction. Ascletis submitted a United States FDA investigational new drug application for the combination in July 2026. ([ascletis.com](https://www.ascletis.com/news_detail/200/id/1415.html))
- Other names
- ASC36 + ASC35
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)AMY receptor (Calcitonin receptor (with ramps))GLP1R (GLP-1R)
Beyond the preview
Go deeper on ASC36_35 FDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC36_35 FDC.